Skip to main content

Table 5 Treatments of enrolled Adult-onset Still’s disease patients at the time of diagnosis

From: Adult-onset Still’s disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers

Treatment

Patients

Steroids, number (%)

100 (100)

Low dose of steroids monotherapy, number (%)

4 (4)

High dose of steroids monotherapy, number (%)

39 (39)

Steroid pulse therapy, number (%)

37 (37)

sDMARD, number (%)

55 (55)

 Methotrexate

43 (43)

 Cyclosporine A

8 (8)

 Hydroxychloroquine

4 (4)

 Cyclophosphamide

2 (2)

 Methotrexate and cyclosporine A

5 (5)

 Methotrexate and hydroxychloroquine

2 (2)

Biologic agents, number (%)

32 (32)

 Infliximab

10 (10)

 Tocilizumab

8 (8)

 Etanercept

7 (7)

 Anakinra

6 (6)

 Certolizumab pegol

1 (1)

Combination therapy, steroids + sDMARD(s), number (%)

25 (25)

Combination therapy, steroids + biologics agent ± sDMARD(s), number (%)

32 (32)

  1. sDMARDs synthetic disease-modifying anti-rheumatic drugs